Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: a multicenter retrospective study
Jiayan Chen,Chunwei Xu,Qian Wang,Jiawen Lv,Wanjun Lu,Yixue Zhang,Yanwen Yao,Xiaoling Gu,Guannan Wu,Yue Hao,Weiwei Pan,Wenxian Wang,Shirong Zhang,Tangfeng Lv,Yong Song,Dong Wang
DOI: https://doi.org/10.1016/j.lungcan.2023.107315
IF: 6.081
2023-07-26
Lung Cancer
Abstract:Background Although the treatment of ERBB2-altered non-small cell lung cancer (NSCLC) has been studied for many years, there are no comprehensive studies to evaluate the benefits of various therapies as first-line treatment. Through the development of immunotherapy, more and more different combination treatments were applicated in clinical practice, therefore, we conducted a multicenter retrospective study to evaluate the efficacy of different treatments. Methods We enrolled patients with ERBB2-altered NSCLC who had undergone at least one-line systemic anticancer treatment to evaluate the efficacy of first-line chemotherapy alone (Chemo), anti-ERBB2 tyrosine kinase inhibitor (TKI), chemotherapy plus immunotherapy (Chemo+Immuno), chemotherapy plus anti-angiogenesis therapy (Chemo+Antiangio) and chemotherapy combined with immunotherapy and anti-angiogenesis therapy (Chemo+Immuno+Antiangio). The clinical outcomes included objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), one-year and three-year survival rate. Results We enroll 36 patients harboring ERBB2 mutation and 29 with ERBB2 amplification. The overall ORR was 30.8%, DCR was 69.2% and mPFS was 5.7 months. Chemo+Immuno and Chemo+Antiangio both achieved longer mPFS than TKI (7.8 vs 3.6 months, HR: 0.24, 95%CI: 0.09-0.64, P = 0.002; 5.9 vs 3.6 months, HR: 0.36, 95%CI: 0.15-0.88, P=0.019; respectively), while there was no significant difference in mPFS between Chemo+Immuno or Chemo+Antiangio and Chemo (both P > 0.05), the mPFS of the first two was longer. For ERBB2-mutant patients, the mPFS was 5.9 months, and Chemo+Immuno and Chemo+Antiangio both achieved longer mPFS than TKI (12.9 vs 2.9 months, HR: 0.15, 95%CI: 0.03-0.68, P=0.005; 7.1 vs 2.9 months, HR: 0.50, 95%CI: 0.29-0.88, P=0.009, respectively). In the same therapies, patients with ERBB2 mutation or ERBB2 amplification showed no statistical significance in PFS (both P > 0.05). Conclusions In the first-line treatment of ERBB2-altered NSCLC, chemotherapy combined with immunotherapy or anti-angiogenesis therapy may have greater survival benefits than ERBB2-target therapy, but the efficacy may not be better than that of chemotherapy.
oncology,respiratory system